About: Artivion     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : dbo:Organisation, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon
http://dbpedia.demo.openlinksw.com/c/5oYCA8ar25

Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive. In December 2017, Artivion acquired JOTEC AG, A German-based company developer of medical devices for aortic and peripheral vascular diseases, for $225 million.

AttributesValues
rdf:type
rdfs:label
  • Artivion (en)
rdfs:comment
  • Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive. In December 2017, Artivion acquired JOTEC AG, A German-based company developer of medical devices for aortic and peripheral vascular diseases, for $225 million. (en)
foaf:name
  • Artivion, Inc. (en)
foaf:homepage
name
  • Artivion, Inc. (en)
location
dct:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
Link from a Wikipage to an external page
sameAs
dbp:wikiPageUsesTemplate
foundation
founder
  • Steve Anderson (en)
homepage
industry
  • Medical Device (en)
key people
  • Mat Packin, Chairman of the Board, President & CEO (en)
location
  • Kennesaw, Georgia, United States (en)
num employees
products
  • Human tissues for transplant, mechanical heart valves, aortic stent grafts, BioGlue (en)
revenue
traded as
  • S&P 600 component (en)
  • NYSE:AORT (en)
type
has abstract
  • Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive. Artivion, Inc. incorporated in 1984 in Florida, was the first biomedical company to specialize in the ultra-low temperature preservation of human heart valves used for cardiac reconstruction, primarily in children born with heart defects. The Company preserves and distributes human tissues and develops, manufactures, and commercializes medical devices for cardiac and vascular transplant applications. The human tissues distributed by Artivion include the CryoValve SG pulmonary human heart valve and the CryoPatch SG pulmonary cardiac patch tissue, both processed using Artivion's proprietary SynerGraft technology. Artivion's medical devices consist of surgical adhesives, sealants, and hemostats including BioGlue Surgical Adhesive, PerClot, which the company began distributing for Starch Medical, Inc. in October 2010, as well as On-X Heart Valves, which they acquired in 2016, and aortic stent grafts manufactured by JOTEC GmbH, which they acquired in 2017. In 2019, Artivion entered a distribution agreement with Endospan.The agreement gives Artivion exclusive European distribution rights to Nexus, an endovascular stent graft system approved for the repair of aneurysms and dissections in the aortic arch. The company preserves small diameter human saphenous vein conduits (3mm to 6mm) for use in peripheral vascular reconstructions and coronary bypass surgery. Failure to achieve revascularization of an obstructed vessel may result in the loss of a limb or even death of the patient. When patients require bypass surgery, the surgeon's first choicegenerally is the patient's own vein tissue. However, in cases of advanced vascular disease, 30% of patients have unsuitable vein tissue for transplantation, and the surgeon must consider using synthetic grafts or preserved human vascular tissue. Small diameter synthetic vascular grafts are generally not optimal for below-the-knee surgeries because they have a tendency to obstruct over time. Preserved human vascular tissues tend to remain open longer and as such are used in indications where synthetics typically fail. In addition, synthetic grafts are not suitable for use in infected areas since they may harbor bacteria and are difficult to treat with antibiotics. Preserved human vascular tissues are ideal grafts for patients with previously infected graft sites. The company also preserves femoral veins and arteries and aortoiliac arteries for bypass or reconstruction within infected surgical areas. In December 2017, Artivion acquired JOTEC AG, A German-based company developer of medical devices for aortic and peripheral vascular diseases, for $225 million. (en)
prov:wasDerivedFrom
page length (characters) of wiki page
founding year
number of employees
revenue ($)
type
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
is Wikipage redirect of
is foaf:primaryTopic of
Faceted Search & Find service v1.17_git147 as of Sep 06 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3331 as of Sep 2 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 53 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software